INIS (Radnostix) Tariff Resilience Score: 7/10 (As of Jul. 04, 2026)


What is Radnostix Tariff Resilience Score?

Radnostix INIS -1.96% Tariff Resilience Score is 7 as of Jul. 04, 2026. The stock has 3 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Radnostix ranks better than 97.09% on this metric.

Radnostix has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Radnostix has International Isotopes has a balanced import/export profile and benefits from some industry-specific exemptions. They have a robust network of alternative suppliers, which mitigates tariff risks. Historical impacts have been minimal.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Radnostix might have Highly Resilient.

Radnostix  (OTCPK:INIS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Radnostix Tariff Resilience Score Related Terms

INIS vs SCYX, BTAI, IXHL: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Radnostix's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radnostix Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Radnostix's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Radnostix's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 7 mean?
Radnostix (INIS) has a Tariff Resilience Score of 7 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Radnostix ranks #30 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Radnostix's Tariff Resilience Score too high?
Radnostix's current Tariff Resilience Score is 7. Based on the distribution chart, Radnostix ranks #30 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Radnostix's Tariff Resilience Score compare to SCYX and BTAI?
According to the Drug Manufacturers industry distribution chart, Radnostix ranks #30 out of 1030 companies for Tariff Resilience Score. This places Radnostix in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Radnostix's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radnostix stock overvalued right now?
Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 40% above its estimated fair value. The current Tariff Resilience Score is 7. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Radnostix (INIS), the current Tariff Resilience Score is 7 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radnostix Business Description

Address 4137 Commerce Circle, Idaho Falls, ID, USA, 83401
Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.